In conclusion, preclinical PI3Kδ inhibition in the TCL1 AT mouse model of CLL reduces the proliferation, expression of activation markers, differentiation, as well as effector function of CD8+ T-cells, which likely contributes to a diminished CLL-control by this cell type. Here, CD8A is linked to B-cell chronic lymphocytic leukemia.